Related Experiment Videos
Changes in serum autoantibodies to thyroid peroxidase during antithyroid drug therapy for Graves' disease
J Takamatsu1, T Hosoya, Y Kohno
1First Department of Medicine, Osaka Medical College, Takatsuki, Japan.
Abstract:
Thyroid microsomal antigen is considered to be identical with thyroid peroxidase (TPO). Although there have been many reports concerning changes in microsomal autoantibody during the course of antithyroid drug therapy for Graves' disease, little is known about this matter in relation to TPO autoantibody (TPOab). Therefore, in this paper, we studied serial changes in the latter autoantibody. Initial levels of serum TPOab (% immunoprecipitation) in 13 patients with hyperthyroid Graves' disease ranged from -11.3% to +84.5% (mean +/- SD, 38.9 +/- 31.8%). Of three patients with persistently increased serum TPOab throughout drug therapy, all had recurrence of hyperthyroidism after the drug was discontinued. Of seven patients whose TPOab levels were initially high but subsequently decreased, four had remission of the disease after drug therapy. Inhibition by TPOab of the TPO activity was also demonstrated by both guaiacol and iodide assays, and changes in this inhibitory activity during therapy varied among individuals. This inhibition was not correlated with disease remission. The decrease in serum TPOab observed in some antithyroid drug-treated patients may reflect a decline in disease activity or may be a direct effect of the drug.
Insights
Thyroid peroxidase autoantibodies (TPOab) levels can predict Graves
Area of Science:
- Endocrinology
- Immunology
- Internal Medicine
Background:
- Graves' disease is an autoimmune disorder characterized by hyperthyroidism.
- Thyroid peroxidase (TPO) is a key antigen in thyroid autoimmunity.
- The role of TPO autoantibodies (TPOab) in the course of Graves' disease treatment is not fully understood.
Purpose of the Study:
- To investigate the serial changes in serum TPO autoantibodies (TPOab) during antithyroid drug therapy for hyperthyroid Graves' disease.
- To explore the relationship between TPOab levels, TPO activity inhibition, and disease remission.
Main Methods:
- Serum TPOab levels were measured using immunoprecipitation in 13 hyperthyroid Graves' disease patients undergoing antithyroid drug therapy.
- TPO activity inhibition was assessed using guaiacol and iodide assays.
- Patients were monitored for disease recurrence or remission after drug discontinuation.
Main Results:
- Initial serum TPOab levels varied significantly among patients.
- Persistently high TPOab levels were associated with hyperthyroidism recurrence after treatment cessation.
- Decreasing TPOab levels were observed in some patients, with four out of seven achieving remission.
- TPOab inhibited TPO activity, but this inhibition did not correlate with disease remission.
Conclusions:
- Serial changes in serum TPOab during antithyroid drug therapy may reflect disease activity or a direct drug effect.
- TPOab levels might serve as a potential indicator for predicting disease recurrence in Graves' disease patients.
- Further research is needed to elucidate the precise mechanisms underlying TPOab changes and their clinical implications.